WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202118
CAS#: 920113-03-7 (HCl)
Description: Riviciclib, also known as P276-00 , is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. P276-00 selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.
MedKoo Cat#: 202118
Name: Riviciclib HCl
CAS#: 920113-03-7 (HCl)
Chemical Formula: C21H21Cl2NO5
Exact Mass: 401.103
Molecular Weight: 438.301
Elemental Analysis: C, 57.55; H, 4.83; Cl, 16.18; N, 3.20; O, 18.25
Riviciclib HCl, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Related CAS #: 920113-03-7 (HCl) 920113-02-6 (free base)
Synonym: P276-00; P-276-00; P 276-00; P-27600; P 27600; P 27600; Riviciclib, Riviciclib HCl
IUPAC/Chemical Name: 2-(2-chlorophenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-chromen-4-one hydrochloride
InChi Key: OOVTUOCTLAERQD-OJMBIDBESA-N
InChi Code: InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1
SMILES Code: O=C1C=C(C2=CC=CC=C2Cl)OC3=C1C(O)=CC(O)=C3[C@H]4[C@H](CO)N(C)CC4.[H]Cl
The following data is based on the product molecular weight 438.301 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines. Lung Cancer. 2013 Nov;82(2):214-21. doi: 10.1016/j.lungcan.2013.08.010. Epub 2013 Sep 3. PubMed PMID: 24051085.
2: Mishra PB, Lobo AS, Joshi KS, Rathos MJ, Kumar GA, Padigaru M. Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma. J Transl Med. 2013 Feb 18;11:42. doi: 10.1186/1479-5876-11-42. PubMed PMID: 23414419; PubMed Central PMCID: PMC3672051.
3: Rathos MJ, Khanwalkar H, Joshi K, Manohar SM, Joshi KS. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer. 2013 Jan 23;13:29. doi: 10.1186/1471-2407-13-29. PubMed PMID: 23343191; PubMed Central PMCID: PMC3635914.
4: Shirsath NP, Manohar SM, Joshi KS. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Mol Cancer. 2012 Oct 18;11:77. doi: 10.1186/1476-4598-11-77. PubMed PMID: 23075291; PubMed Central PMCID: PMC3558400.
5: Gallorini M, Cataldi A, di Giacomo V. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs. 2012 Dec 1;26(6):377-91. doi: 10.2165/11634060-000000000-00000. Review. PubMed PMID: 22928661.
6: Rathos MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. J Transl Med. 2012 Aug 8;10:161. doi: 10.1186/1479-5876-10-161. PubMed PMID: 22873289; PubMed Central PMCID: PMC3478973.
7: Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012 Mar;15(1):15-27. doi: 10.1038/pcan.2011.51. Epub 2011 Nov 15. PubMed PMID: 22083267.
8: Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res. 2011 Jun;35(6):821-30. doi: 10.1016/j.leukres.2010.12.010. Epub 2011 Jan 8. PubMed PMID: 21216463.
9: Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009 May;23(5):961-70. doi: 10.1038/leu.2008.378. Epub 2009 Jan 8. PubMed PMID: 19151776.
10: Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig HH, Sharma S. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34. PubMed PMID: 17363487.
11: Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918-25. PubMed PMID: 17363486.
Vouciclib is a Me-Too version of Riviciclib. Their structure is very similar (see below side-by-side comparison.
